New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 30, 2014
07:39 EDTCVS, CAHCardinal Health sees CVS Caremark venture operational as soon as July 1
In December 2013, Cardinal Health (CAH) and CVS Caremark (CVS) announced the signing of an agreement to form the largest generic sourcing entity in the U.S. Both companies are contributing their sourcing and supply chain expertise to the 50/50 joint venture and are committing to source generic drugs through it. The U.S.-based joint venture is expected to be operational as soon as July 1 and will have an initial term of 10 years, Cardinal said.
News For CAH;CVS From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
March 3, 2015
07:56 EDTCAHCardinal Health price target raised to $105 from $90 at Argus
Argus increased its price target on Cardinal based on what the firm sees as the company's solid Q2 results and its beneficial acquisition of Johnson & Johnsonís (JNJ) Cordis business. Argus expects Cordis to provide Cardinal with a new growth driver with higher margins. Argus keeps a Buy rating on Cardinal.
07:24 EDTCAHAmerisourceBergen can mitigate loss of PharMerica deal, says RBC Capital
Subscribe for More Information
March 2, 2015
16:26 EDTCAHOn The Fly: Closing Wrap
Subscribe for More Information
12:13 EDTCAHOn The Fly: Midday Wrap
Subscribe for More Information
11:52 EDTCAHJohnson & Johnson EPS dilution from Cordis deal seems modest, says Wells Fargo
Wells Fargo estimates that Johnson & Johnson's (JNJ) planned sale of Cordis to Cardinal Health (CAH) should dilute J&J yearly EPS by about 3c-4c, assuming all is else equal, and the firm expects the company to be able to absorb at least some of this dilution and possibly offset the rest via share repurchases. Wells maintains its Outperform rating on J&J shares.
08:12 EDTCAHPharMerica announces wholesale agreement with Cardinal Health
PharMerica Corporation (PMC) announced that it has entered into a new wholesale drug distribution agreement with Cardinal Health (CAH). The new agreement will take effect on April 1 and extend through June 2018. As part of the agreement, Cardinal Health will assume responsibility for the sourcing and distribution of branded and generic pharmaceuticals for PharMerica.
08:01 EDTCAHCardinal Health offers to buy Cordis from Johnson & Johnson in $1.99B deal
Subscribe for More Information
07:53 EDTCAHCardinal Health to host conference call
Subscribe for More Information
07:35 EDTCAHCardinal Health to buy Cordis from Johnson & Johnson in $1.99B deal
Subscribe for More Information
07:35 EDTCAHCardinal Health to acquire Cordis for $1.94B in cash
Cardinal Health (CAH) announced plans to acquire Johnson & Johnson's (JNJ) Cordis business, a global manufacturer of cardiology and endovascular devices, for $1.94B in cash, or approximately $1.59B, net of the present value of tax benefits. The acquisition is expected to be financed with a combination of $1B in new senior unsecured notes and the remainder with existing cash. The transaction is expected to close in the United States and key non-U.S. countries towards the end of calendar 2015. Assuming this timing, Cardinal Health expects fiscal 2017 accretion in non-GAAP diluted earnings per share from continuing operations of greater than 20c per share, which includes the cost of an incremental 7c-8c per share of interest expense associated with financing the transaction. The company expects the acquisition to be increasingly accretive thereafter and assumes that synergies will exceed $100M annually by the end of fiscal 2018. Cordis had annual sales in 2014 of approximately $780M, split almost evenly between cardiology and endovascular products. Upon completion of that process, Cardinal Health expects to enter into a definitive purchase and sale agreement in respect of the proposed acquisition. The proposed transaction will also be subject to customary closing conditions, including regulatory approvals, and is expected to close in the approximately 20 principal countries towards the end of calendar year 2015 and in the remaining countries on a rolling basis afterward.
February 26, 2015
11:50 EDTCAHCardinal Health management to meet with William Blair
Subscribe for More Information
February 24, 2015
13:23 EDTCVSLeerink healthcare technology analyst holds analyst/industry conference call
Healthcare Tech & Distribution Analyst Larsen discusses th 2016 Pharmacy Benefits Management (PBM) selling season, the impact of the Hep C PBM formulary negotiations on the selling season and specialty drug trend and areas of opportunity for PBMs on an Analyst/Industry conference call to be held on March 5 at 2 pm.
07:31 EDTCAHRBC Capital to hold a conference
Subscribe for More Information
February 22, 2015
12:51 EDTCAHJ&J considers Cordis sale with Cardinal the leading suitor, Bloomberg says
Subscribe for More Information
February 20, 2015
17:31 EDTCAHJ&J considering sale of Cordis with Cardinal the leading suitor, Bloomberg says
Subscribe for More Information
February 17, 2015
10:01 EDTCVSCVS says PCSK9 inhibitors could cost system $150B annually
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use